Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

Walleye Capital LLC purchased a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 498,490 shares of the company’s stock, valued at approximately $3,450,000. Walleye Capital LLC owned 0.92% of Upstream Bio at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Upstream Bio in the 4th quarter valued at $78,264,000. Vanguard Group Inc. lifted its stake in shares of Upstream Bio by 12.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock worth $45,944,000 after acquiring an additional 271,718 shares during the period. UBS Group AG lifted its stake in shares of Upstream Bio by 563.4% in the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock worth $49,039,000 after acquiring an additional 1,533,972 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Upstream Bio in the fourth quarter valued at about $41,423,000. Finally, State Street Corp increased its stake in shares of Upstream Bio by 18.4% during the fourth quarter. State Street Corp now owns 1,319,226 shares of the company’s stock worth $35,817,000 after acquiring an additional 204,645 shares during the period.

Upstream Bio Stock Performance

Shares of NASDAQ UPB opened at $7.07 on Friday. The firm has a market capitalization of $387.22 million, a P/E ratio of -2.44 and a beta of 1.26. Upstream Bio, Inc. has a one year low of $5.85 and a one year high of $33.68. The company’s fifty day moving average is $6.81 and its two-hundred day moving average is $9.90.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The business had revenue of $0.77 million for the quarter, compared to analysts’ expectations of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. On average, sell-side analysts forecast that Upstream Bio, Inc. will post -2.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

UPB has been the subject of several analyst reports. Wall Street Zen cut shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday. Truist Financial lowered their price objective on Upstream Bio to $25.00 and set a “buy” rating on the stock in a report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Upstream Bio in a research report on Monday, August 3rd. Mizuho cut their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Finally, HC Wainwright began coverage on Upstream Bio in a research note on Wednesday, June 3rd. They set a “buy” rating and a $36.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $29.67.

Key Headlines Impacting Upstream Bio

Here are the key news stories impacting Upstream Bio this week:

• Positive Sentiment: JPMorgan raised its price target for Upstream Bio (UPB) from $8 to $9 while maintaining a “Neutral” rating. The revised target implies approximately 27.3% upside from the referenced share price, providing a modest positive catalyst despite the unchanged cautious rating. Benzinga article
• Positive Sentiment: HC Wainwright retained its “Buy” rating and $36 price target, indicating substantial potential upside if Upstream Bio’s pipeline and development plans progress successfully. MarketBeat analyst coverage
• Neutral Sentiment: HC Wainwright’s revised forecasts continue to project losses, including estimated 2026 earnings of negative $3.09 per share and negative $0.79 and $0.82 per share for the third and fourth quarters, respectively. The firm’s “Buy” rating remains unchanged, but the estimates point to a lengthy path toward profitability.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026–2030: 2027 to negative $3.31 from negative $3.09, 2028 to negative $3.13 from negative $2.92, 2029 to negative $3.56 from negative $3.35, and 2030 to negative $3.84 from negative $3.42. These broader expected losses may weigh on investor sentiment and offset the benefit of JPMorgan’s target increase. MarketBeat analyst estimates

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.